. 2003 Apr 29;88(9):1394–1399. doi: 10.1038/sj.bjc.6600890

Table 3. Breast cancer risks for quartiles of oestrone, oestradiol, testosterone and 5α-androstane-3α, 17β-diol.

	Women in subcohort (n=382)	Breast cancer cases (n=364)	IRR^a	95% CI	IRR^b	95% CI
Oestrone^a
0.06–1.19 ng mg⁻¹	95	57	1.0	—	1.0	—
1.19–1.77 ng mg⁻¹	95	95	1.9	1.2–3.0	1.9	1.2–3.0
1.78–2.50 ng mg⁻¹	95	79	1.2	0.8–2.0	1.2	0.8–2.0
>2.50 ng mg⁻¹	95	132	2.5	1.6–3.8	2.4	1.5–3.8
P_trend				0.001		0.002

Oestradiol
0.08–0.34 ng mg⁻¹	95	77	1.0	—	1.0	—
0.34–0.49 ng mg⁻¹	96	79	1.1	0.7–1.7	1.1	0.7–1.7
0.49–0.77 ng mg⁻¹	96	101	1.4	0.9–2.1	1.4	0.9–2.1
>0.77 ng mg⁻¹	95	107	1.5	1.0–2.3	1.5	1.0–2.3
P_trend				0.03		0.03

Testosterone
0.03–1.85 ng mg⁻¹	96	80	1.0	—	1.0	—
1.86–2.71 ng mg⁻¹	95	78	1.1	0.7–1.7	1.1	0.7–1.7
2.72–4.16 ng mg⁻¹	96	97	1.5	0.9–2.3	1.5	1.0–2.3
>4.16 ng mg⁻¹	95	109	1.6	1.0–2.4	1.6	1.0–2.4
P_trend				0.02		0.02

5α-androstane-3α, 17β-diol^c
0.85–15.93 ng mg⁻¹	95	62	1.0	—	1.0	—
15.94–23.67 ng mg⁻¹	96	103	1.7	1.1–2.7	1.7	1.1–2.7
23.68–33.65 ng mg⁻¹	96	101	1.7	1.1–2.6	1.7	1.1–2.6
>33.65 ng mg⁻¹	95	97	1.7	1.1–2.7	1.8	1.1–2.8
P_trend				0.03		0.03
^aAdjusted for family history of breast cancer (yes/no). ^bAdditional adjustment for BMI. ^cMeasurements for oestrone were missing in one case and two women from the subcohort. Measurements for 5α-androstane-3α, 17β-diol was missing for one case. IRR, incidence rate ratio.